Clinical Issues in Atopic DermatitisDebates and Discussion About Managing Moderate-To-Severe Disease
Atopic Dermatitis Overview and Pathogenesis
Czarnowicki T, et al. J Allergy Clin Immunol. 2019;143(1):1-11.
Paternoster L, et al. J Allergy Clin Immunol. 2018:141(3):964-971.
Age-specific changes in the molecular phenotype of patients with moderate-to-severe atopic dermatitis.
Zhou L, et al. J Allergy Clin Immunol. 2019;144(1):144-156.
Peng W, Novak N. Clin Exp Allergy. 2015;45(3):566-574.
Patient Burden and Comorbidities
Determinants of disease severity among patients with atopic dermatitis: association with components of the atopic march.
Holm JG, et al. Arch Dermatol Res. 2019;311(3):173-182.
Kim JP, et al. J Am Acad Dermatol. 2016;75(4):681-687.
Mitchell AE. Psychol Res Behav Manag. 2018;11:289-298.
Paller AS, et al. J Allergy Clin Immunol. 2019;143(1):46-55.
Association of inadequately controlled disease and disease severity with patient-reported disease burden in adults with atopic dermatitis.
Simpson EL, et al. JAMA Dermatol. 2018;154(8):903-912.
Management of Atopic Dermatitis
Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis.
Bakker DS, et al. Br J Dermatol. 2019;180(5):1248-1249.
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.
Blauvelt A, et al. Lancet. 2017;389(10086):2287-2303.
Boguniewicz M, et al. Ann Allergy Asthma Immunol. 2018;120(1):10-22.
Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement.
Drucker AM, et al. Br J Dermatol. 2018;178(3):768-775.
Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort.
Faiz S, et al. J Am Acad Dermatol. 2019;81(1):143-151.
Horimukai K, et al. J Allergy Clin Immunol. 2014;134(4):824-830.
Ruzicka T, et al. N Engl J Med. 2017;376(9):826-835.
Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE).
Simpson EL, et al. J Am Acad Dermatol. 2018;78(5):863-871.
When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council.
Simpson EL, et al. J Am Acad Dermatol. 2017;77(4):623-633.
Simpson EL, et al. N Engl J Med. 2016;375(24):2335-2348.
Wollenberg A, et al. J Allergy Clin Immunol. 2019;143(1):135-141.
Clinical Insights Into Atopic Dermatitis Pathogenesis
This short video discusses the pathophysiology of atopic dermatitis, illustrating how it is a disease of both barrier dysfunction and Th2-driven inflammation. Among Th2 cytokines, IL-4 and IL-13 have demonstrated a key role in AD pathogenesis, which has led to the development of a human monoclonal antibody against IL-4Rα for the treatment of moderate-to-severe disease.
Pathophysiology to the Management of Moderate-to-Severe Disease
New Strategies to Target Remission and Individualize Comprehensive Care
Targeting Immune Dysregulation and Delivering Comprehensive Care
Looking Beyond Barriers to Optimize Therapy
Debates and Discussions About Pustular Disease Subtypes
Collaborative Care for Better Patient Outcomes